<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-QSB

/x/      QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

                    FOR QUARTERLY PERIOD ENDED JUNE 30, 2003

                                       OR

/X/      TRANSITION  REPORT  PURSUANT  TO SECTION 13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

         FOR THE TRANSITION PERIOD FROM  ____________ TO________________

                         COMMISSION FILE NUMBER 0-49824
                           INAMCO INTERNATIONAL, CORP.

         (Exact name of small business issuer as specified in its charter)

                 DELAWARE                              72-1359595
      (STATE OR OTHER JURISDICTION OF               (I.R.S. EMPLOYER
      INCORPORATION OR ORGANIZATION)               IDENTIFICATION NO.)

  801 Montrose Ave., South Plainfield, NJ                 07080
           (ADDRESS OF PRINCIPAL                       (ZIP CODE)
            EXECUTIVE OFFICES)

                                 (908) 754-4880
              (REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes /x / No / /

    Indicate the number of shares outstanding of each of issuer's classes of
                common stock, as of the latest practicable date.

         COMMON STOCK, $0.00001
               PAR VALUE                            27,600,000 SHARES
    ------------------------------       -----------------------------------
                 Class                    Outstanding as of August 20, 2003



<PAGE>

                           INAMCO INTERNATIONAL, CORP.

                                      INDEX
<TABLE>
<CAPTION>
                                                                                                    PAGE
                                                                                                     NO.
                                                                                                  --------
                                      PART I. FINANCIAL INFORMATION

<S>          <C>                                                                                     <C>
Item 1.      Financial Statements (Unaudited)                                                         3

             Condensed Balance Sheets--As of June 30, 2003 and December 31, 2003                      3

             Condensed Statements of Operations--Six and Three Month Periods Ended June 30,           4
             2003 and 2002

             Condensed Statements of Cash Flows--Six Month Periods Ended June 30, 2003 and 2002       5

             Notes to Condensed Financial Statements                                                  6

Item 2.      Management's Discussion and Analysis of Financial Condition and Results of               8
             Operations

Item 3.      Controls and Procedures                                                                 10

                                        PART II. OTHER INFORMATION

Item 4.      Exhibits and Reports on Form 8-K                                                        11

Signatures                                                                                           12
Certification                                                                                        13
Exhibit 99.1                                                                                         14

</TABLE>



                                        2


<PAGE>

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS


                           Inamco International, Corp.

                            Condensed Balance Sheets
<TABLE>
<CAPTION>
                                                           June 30,         December 31,
                                                             2003               2002
                                                      ------------------ --------------------
                                                         (unaudited)           (Note)
ASSETS
Current assets:
<S>                                                   <C>                <C>
  Cash                                                $              137 $              927
                                                      ------------------ --------------------
   Total Current Assets                                              137                927
  Other Assets                                        $              213 $              213
                                                      ------------------ --------------------
Total Assets                                          $              350 $            1,140
                                                      ================== ====================
LIABILITIES AND STOCKHOLDERS' DEFICIENCY
Current liabilities:
  Accounts payable and accrued expenses               $            8,457 $            5,615
                                                      --------------------------------------
   Total Current liabilities                                       8,457              5,615
  Due to Officers/Shareholders                                    13,868              8,069
                                                      --------------------------------------
   Total Liabilities                                              22,325             13,684
Stockholders' Deficiency:
  Common stock, $0.00001 par value;
  Authorized: 50,000,000 shares
  Issued and Outstanding: 27,600,000 shares                          276                276
  Additional paid-in capital                                      22,804             22,804
  Deficit Accumulated in the Development Stage                   (45,055)           (35,624)
                                                      ================== ====================
Total Stockholders' Deficiency                                   (21,975)           (12,544)
                                                      ------------------ --------------------
Total liabilities and stockholders' equity            $              350 $            1,140
                                                      ================== ====================
</TABLE>

Note:    These  balance  sheets  have  been  derived  from  unaudited  financial
         statements  and do not include  all of the  information  and  footnotes
         required  by  accounting  principles  generally  accepted in the Unites
         States for complete financial statements.

See accompanying notes to condensed financial statements.



                                        3
<PAGE>

                           Inamco International, Corp.

                       Condensed Statements of Operations
                                   (Unaudited)


<TABLE>
<CAPTION>
                                                               Three months ended
                                                                    June 30,
                                                      -------------------------------------
                                                             2003               2002
                                                      ------------------ ------------------
<S>                                                   <C>                <C>
Revenues
  Total revenues                                      $               -- $               --

Cost and Expenses
Bank Charges and Miscellaneous                                        45                500
Professional and Consulting Fees                                   7,767                 --
                                                      ------------------ ------------------
  Total operating expenses                                         7,812                500
  Net Loss                                            $           (7,812)$             (500)
                                                      ================== ==================
Net (loss) per share                                  $            (0.00)$            (0.00)
                                                      ================== ==================
Weighted Average Number of Shares Outstanding                 27,600,000         27,600,000
                                                      ================== ==================



                                                                Six months ended
                                                                    June 30,
                                                      -------------------------------------
                                                             2003               2002
                                                      ------------------ ------------------
Revenues
  Total revenues                                      $               -- $               --

Cost and Expenses
Bank Charges and Miscellaneous                                        90                500
Professional and Consulting Fees                                   9,342                 --
                                                      ------------------ ------------------
  Total operating expenses                                         9,432                500
  Net Loss                                            $           (9,432)$             (500)
                                                      ================== ==================
Net (loss) per share                                  $            (0.00)$            (0.00)
                                                      ================== ==================
Weighted Average Number of Shares Outstanding                 27,600,000         27,600,000
                                                      ================== ==================

</TABLE>




                                        4

<PAGE>


<TABLE>
<CAPTION>


                                                                 Inception (January
                                                                  17, 1993) to June
                                                                         30,
                                                                 ------------------
                                                                        2003
                                                                 ------------------
            Revenues
<S>                                                              <C>
             Total revenues                                      $               --

            Cost and Expenses
            Bank Charges and Miscellaneous                                      263
            Professional and Consulting Fees                                 44,792
                                                                 ------------------
             Total operating expenses                                        45,055
             Net Loss                                            $          (45,055)
                                                                 ==================
            Net (loss) per share                                 $            (0.00)
                                                                 ==================
            Weighted Average Number of Shares Outstanding                27,600,000
                                                                 ==================

</TABLE>



                   Condensed Cash Flow Statements (Unaudited)

<TABLE>
<CAPTION>
                                                                 Six months ended June 30,
                                                        --------------------------------------
                                                                 2003                2002
                                                        -------------------- -----------------
<S>                                                     <C>                   <C>
Cash Flows from Operating Activities
Net income (loss)                                       $           (9,432)   $           (500)
Adjustments to reconcile net loss to net cash used
in operating activities:                                                                    --
  Change in accrued expenses                                         2,842              (1,668)
                                                        -------------------- -----------------
Net cash used for operating activities                              (6,590)              (2,168)

Cash Flows from Investing Activities
  Change in other assets                                                --                  --
Net cash used for investing activities                                  --                  --

Cash Flows from Financing Activities
  Loans from officer/shareholder, net of repayments                  5,800               2,168
  Restricted common stock issued in payment of
  expenses                                                              --                  --
                                                        -------------------- -----------------
Net cash provided by financing activities                            5,800               2,168
NET INCREASE (DECREASE) IN CASH                                       (790)                 --
Cash at beginning of period                                            927                  38
                                                        -------------------- -----------------
Cash at end of period                                   $              137   $             38
                                                        ==================== =================
</TABLE>


See accompanying notes to condensed financial statements.

                                        5
<PAGE>

NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS

1. Basis of Presentation

         In the  opinion of  management,  all  adjustments,  consisting  only of
normal  recurring  adjustments  necessary for a fair statement of (a) results of
operations  for the six and three month periods ended June 30, 2003 and 2002 (b)
the financial  position at June 30, 2003,  and (c) the  statements of cash flows
for the six month  period  ended  June 30,  2003 and 2002 have  been  made.  The
results of  operations  for the six and three months ended June 30, 2003 are not
necessarily indicative of the results to be expected for the full year.

         The accompanying  unaudited financial  statements have been prepared in
accordance with generally accepted  accounting  principles for interim financial
information.  Accordingly, they do not include all the information and footnotes
required by generally accepted accounting  principles for financial  statements.
For further  information,  refer to the audited  financial  statements and notes
thereto for the year ended  December  31, 2002  included in the  Company's  Form
10-KSB filed with the Securities and Exchange Commission on April 15, 2003.

         The  preparation of financial  statements in accordance with accounting
principles  generally accepted in the United States requires  management to make
estimates  and  assumptions  that  affect  amounts  reported  in  the  condensed
financial statements and related footnotes.  Changes in the estimates may affect
amounts reported in future periods.
         The  Company's  financial  statements  have been  presented  on a going
concern basis, which contemplates the realization of assets and the satisfaction
of liabilities in the normal course of business.  The Company has no significant
assets,  no revenues  and has had losses since  inception.  The Company can only
become a viable going  concern if it obtains  additional  capital and acquires a
viable operating company.

2. Net Loss Per Share

    In  accordance  with SFAS No. 128,  Earnings Per Share basic and diluted net
loss per share  are  computed  by  dividing  the net loss for the  period by the
weighted average number of common shares outstanding during the period.

3. Comprehensive Loss

    Comprehensive loss for all periods presented is the same as net loss.

4. Deferred Stock Compensation

    For the six months ended June 30, 2003 and 2002, in connection with advisory
and  consultation to second party firms,  the Company recorded no deferred stock
compensation.


5. Non-cash Preferred Stock Charge

    For the six months  ended June 30, 2003 and 2002,  the  Company  recorded no
sale of any forms of Preferred Stock.




                                        6

<PAGE>





6. Capital Purchase of Common Stock by a Privately Held Business

    On October 26, 1999, the Company, which was previously known as Omni Assets,
Inc. (a "non-operating"  public shell),  sold 22,273,890 of its common shares of
stock  to  Inamco  International  Corp.  (a  privately  held  corporation).  The
acquisition was deemed to be a capital purchase, by privately held corporations,
of the majority  amount of common  shares owned by Omni Assets,  Inc. In January
2000,  Omni then  purchased  the name of "Inamco  International  Corp.",  and in
February 2000, the Company  changed it name from "Omni Assets,  Inc." to "Inamco
International Corp.". The listing symbol was changed from "OMNA" to "IICO" . The
Company currently has a total number of shares outstanding equal to Twenty Seven
Million Six Hundred Thousand (27,600,000).

The following table provides information  pertaining to owners of more than five
percent of any class of the Company's common stock.

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
          (1)                           (2)                                  (3)                  (4)
     Title of Class               Name and Address                    Amount and Nature      Percentage of
                                  of Beneficial Owner                 of BeneficialOwner     Ownership
-------------------------------------------------------------------------------------------------------------
<S>                                      <C>                                 <C>                   <C>

     Common A                  Inamco Services Corp.*                    12,947,487              46.91%
                              801 Montrose Ave.
                            South Plainfield, NJ  07080

     Common A              Advanced Diagnostics Inc.*                     8,326,403              30.17%
                              801 Montrose Ave.
                            South Plainfield, NJ  07080

Security ownership of management.

The following table provides information pertaining to shares beneficially owned
by all directors and nominees.


-------------------------------------------------------------------------------------------------------------
          (1)                           (2)                                  (3)                  (4)
     Title of Class               Name and Address                    Amount and Nature      Percentage of
                                  of Beneficial Owner                 of BeneficialOwner     Ownership
-------------------------------------------------------------------------------------------------------------

     Common A                         Varges George*                        22,273,890         3.62%
                                    President/Secretary

</TABLE>

         * It should be noted that Mr. Varges George is the sole  shareholder of
Inamco  Services  Corp.,  and Advanced  Diagnostics  Inc., as described  herein.
Accordingly,  Mr. George has direct  control of  approximately  80.70% of Inamco
International,  Corp.  outstanding  common  shares of stock.  He owns  1,000,000
shares directly in his name.

 7. Follow-on Offering of Common Stock

    For the six  months  ended  June 30,  2003 and  2002,  the  Company  has not
recorded and/or performed any secondary or private offering sale of securities.




                                        7


<PAGE>


ITEM 2. MANAGEMENT'S  DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS

This  discussion and analysis  should be read in conjunction  with our financial
statements  and  accompanying  notes  included in this report and the  financial
statements  and notes  thereto for the interim  period  ended  December 31, 2002
included in the Company's Form 10, as amended, as well as Form 10-KSB filed with
the Securities and Exchange Commission on April 15, 2003.

         Operating  results are not  necessarily  indicative of results that may
occur in future periods.


         This discussion and analysis contains  forward-looking  statements that
involve risks,  uncertainties  and assumptions.  Inamco assumes no obligation to
update any  forward-looking  statement contained in this Form 10.The Company has
had no change in its financial  condition as a result of any operations,  nor is
there  any  liquidity,  capital  resources,  results  of  operation,   financial
statements for any interim periods,  material changes in financial position,  or
material changes from the result of operations.


         Certain  statements  contained  in this report on Form 10-QSB and other
public statements that are not historical facts, including those statements that
refer to our plans, goals, objectives, expectations,  strategies, intentions and
beliefs,  constitute  "forward-looking  statements"  within  the  meaning of the
Private  Securities  Litigation  Reform  Act of  1995.  In some  cases,  you can
identify  forward-looking  statements  by  terminology  such as  "will,"  "may,"
"should,"   "expects,"   "plans,"   "anticipates,"    "believes,"   "estimates,"
"predicts,"  "potential,"  "continue,"  or similar  words.  You should not place
undue reliance on these  forward-looking  statements.  These statements  involve
risks  and  uncertainties  that may  cause  actual  results  or events to differ
materially from those expressed or implied in our forward-looking statements. We
assume no obligation to update these forward-looking statements as circumstances
change in the future.


         Inamco   at   present   is  a   company   that  is  in   search   of  a
merger/acquisition candidate in the generic pharmaceutical sector The Company is
still in the development stage, and has had no resources to date.  Consequently,
the Company will need infusions of working  capital either in the form of equity
investments,  loans or otherwise, in order to merge and acquire a pharmaceutical
concern.

         At  present,  the Company has yet to  commence  any  operations  and is
seeking  a proper  merger  and  acquisition  candidate  to  operate  within  the
pharmaceutical  drug  sector.  The  proper  candidate  will  be  an  established
pharmaceutical  company that  presently  manufactures  and  distributes  certain
generic  over-the-counter  ("OTC")  drugs.  The candidate  will need to have the
ability  to  manufacture   generic  drugs  whose   equivalents  are  Actifed(R),
Allerest(R), Anacin(R), Co-Tylenol(R),  Exlax(R), Sudafed(R), and NyQuil(R). The
candidate  will also be in the  position  to  produce  other  OTC  drugs  and/or
"grand-fathered" prescription medications.

         Generic  pharmaceuticals,  as a  whole,  have  the  same  chemical  and
therapeutic  properties as their brand-named  counterparts.  Although  typically
less expensive, they are required to meet the same governmental standards as the
brand-name drug, and most must receive approval from the appropriate  regulatory
authority prior to manufacture and sale. A manufacturer cannot produce or market
a  generic  pharmaceutical  until  all  relevant  patents  (and  any  additional
government-mandated market exclusivity periods) covering the original brand-name
product have expired.




                                        8

<PAGE>

         Once a merger and/or acquisition is consummated,  Inamco plans to be in
a  position  to  sell  its   products  to   distributors   (both   domestic  and
international),   hospitals,   and  large  buying  groups.  The  Food  and  Drug
Administration  ("FDA")  oversees the manufacture of both brand-name and generic
pharmaceuticals, and the production of these drugs is usually subject to:

(1)      An approved New Drug Application ("NDA") which allows the medication to
         state both its safety and effectiveness;
(2)      Marketed under an NDA for safety only;
(3)      Marketed without an NDA; or
(4)      Marketed pursuant to over-the-counter monograph regulations.

          For generic  pharmaceuticals  being  manufactured  for both safety and
effectiveness,  prior  to  marketing,  these  drugs  must  undergo  and  pass an
Abbreviated New Drug Application ("ANDA"). The Company realizes that in order to
get approval from the FDA via an ANDA, all drug product  applications  will need
to  include:  data  relating to product  formulation,  raw  material  suppliers,
stability  information,   manufacturing  techniques,  packaging,  labeling,  and
quality control information. Those drugs subject to an ANDA under the Drug Price
Competition  and Patent Term  Restoration Act of 1984 (the  "Waxman-Hatch  Act")
must  also  contain  bio-equivalency  data.  Generics  can also be  marketed  by
adhering to FDA enforcement  policies, or be subject to an over-the-counter drug
review monograph process.

          If a  successful  merger and  acquisition  is  consummated,  it is the
Company's  belief  that all OTC  medicines  being  produced  will have prior FDA
approvals,  which will give the Company the ability to spend a minimal amount of
time and capital on research  and  development  before raw  materials  reach the
manufacturing stage.

         Inamco  will have also  identified  many  different  sourcing  chemical
companies  where raw materials will be purchased in bulk for the  manufacture of
their generic  pharmaceuticals.  All raw chemicals needed are readily available;
however,  it will be the Company's  intention to always be conscious of pricing,
for  certain  chemical  companies  will give  discounts  when buying in bulk and
placing  continual   orders.   Inamco  will  benefit  from  the  fact  that  the
pharmaceutical  industry is  non-cyclical  and the need for quality OTC drugs is
always present.

           If a merger and acquisition is consummated, the Company plans to have
its good manufacturing  procedures ("GMP") certification issued by the FDA. This
certification  will  allow  Inamco to  produce  a  complete  retail  line of OTC
pharmaceuticals  for  immediate  sale  to its  clientele.  Coinciding  with  the
expected  revenues  generated,  Inamco will also submit  several  different ANDA
applications  to the  FDA,  so  that  it may  manufacture  certain  prescription
medication and add considerable  profit  potential to its entire  pharmaceutical
operation.

         It will be Inamco's intention not to have a single customer or group of
customers  comprising  more than 20% of its revenue  stream.  The  Company  will
continue to add to its client base by tendering  offers  through  certain buying
groups,   municipalities,   government   agencies,   and   hospital  and  retail
distributors.  This will ensure  enough of a customer  base, so that the loss of
any one client will not significantly affect the Company's revenue stream.

         Since the Company has yet to begin any operations, it has no backlogged
orders or government  contracts  subject to renegotiation or termination.  It is
contemplated,  that if a merger and acquisition is successful,  the Company will
have competition  with other  manufacturers  of generic  pharmaceuticals.  These
competitors  will probably have  substantially  greater  capital  resources than
Inamco,  as well as  seasoned  sales and  marketing  teams in  place.  It is the
Company's  belief that its primary  competition  will come from Alpharma,  Inc.,
Barr Laboratories,  Inc., and Geneva Pharmaceuticals,  Inc. However, the generic
market is  currently  estimated to account for  approximately  11% of all global
pharmaceutical  sales,  based on published  reports  included  herein,  and this
figure is  anticipated  to rise  dramatically  as branded drugs come  off-patent
within the next  decade.  It will also be one of Inamco's  commitments  to bring
niche products to market that its  competition  currently finds to burdensome to
manufacture.


                                        9

<PAGE>

         Inamco  has not spent  any  monies on  company-sponsored  research  and
development  activities,  and  there  are no plans  to do so in the  foreseeable
future.  Once a merger and  acquisition is  consummated,  the Company will be in
compliance  with all  federal,  state and local  provisions  with respect to the
manufacture  of  generic  pharmaceuticals.  The FDA  will  oversee  and  enforce
compliance for good manufacturing  practices, and the Company's facility will be
located in a properly  zoned  manufacturing  area.  And,  although  the  Company
presently  has no  employees,  it is  estimated  that a minimum  of 3 doctors of
pharmacology and 10 technicians will be employed.





RESULTS OF OPERATIONS

SIX MONTHS ENDED JUNE 30, 2003 AND 2002

Revenues

    None. For the six and three months ended June 30, 2003 and 2002, the Company
has had no revenue.

Research and Development

    None.  For the six and  three  months  ended  June  30,  2003 and 2002 , the
Company has performed no research and development whatsoever.

General and Administrative

    General and administrative  expenses are minimal,  and for the six and three
months ended June 30, 2003 were $9,432 and $7,812 respectively  compared to $500
and $500 for the same periods in June 2002. General and administrative  expenses
consist  primarily of  supporting  administration  of a public  company and some
professional fees. We expect that our general and  administrative  expenses will
increase substantially once a merger and/or acquisition is consummated, in order
to support our growth and requirements as a public company.

Non-Cash Stock-Based Compensation Charges

    None.  For the six months ended June 30,  2003,  the Company has not had any
non-cash stock based deferred compensation.

Other Income, net

    None. For the six months ended June 30, 2003 and the year ended December 31,
2002, the Company has had no other income.


Research and Development

    None. For the six months ended June 30, 2003 and the year ended December 31,
2002, the Company has performed no research and development whatsoever.

Non-Cash Stock-Based Compensation Charges

    None. For the six months ended June 30, 2003 and the year ended December 31,
2002, the Company has not had any non-cash stock based deferred compensation.

Other Income, net

    None.  For the six months ended June 30, 2003 and 2002,  the Company has had
no other income.

                                       10

<PAGE>

LIQUIDITY AND CAPITAL RESOURCES

    As of  June  30,  2003,  we have  accumulated  a  deficit  of  $45,055.  Our
accumulated  deficit is the result of expenses  incurred in connection  with the
acquisition of the Company and general and administrative  expenses. To date, we
have funded our operations  solely  through loans from the majority  shareholder
and president of the Company, Mr. Varges George.

    As of June 30, 2003,  we had $137 in cash and cash  equivalents  compared to
$927 in cash and cash equivalents as of December 31, 2002.

    Net cash used for  operations  during the six months ended June 30, 2003 was
$6,590 compared to $2,168 for the same quarter in 2002. Net cash provided by Mr.
Varges George was approximately $5,800 during the six months ended June 30, 2003
compared to $2,168 for the same quarter last year.


    Our Company has had no business and/or operating history, and the success of
the Company depends,  in part, upon the successful  performance of the president
and chief  operating  officer,  Mr. Varges George.  The Company will continue to
seek out acquisition candidates, but there can be no assurances that the Company
will ever have any revenues or be profitable or achieve  positive cash flow from
operations.

    We are currently  negotiating a merger which we contemplate  will take place
in mid  2003.  Our  funding  requirements  may  change  at any  time due to fees
associated  with  our  acquisition  negotiations  as well as costs  required  to
complete  such  tasks.  Our  future  capital  requirements  will also  depend on
numerous other factors,  including  scientific  progress,  additional  personnel
costs,  progress  in drug  testing,  the  time  and  cost  related  to  proposed
regulatory approvals,  if any, and the costs of filing certain applications.  We
cannot  assure  you  that  adequate  funding  will  be  available  to us or,  if
available,  that  such  funding  will be  available  on  acceptable  terms.  Any
shortfall  in  funding  could  result in the  curtailment  of our  developmental
efforts.

Item 3.   CONTROLS AND PROCEDURES

(a)     Evaluation of Disclosure Controls and Procedures.

Within the 90 days prior to the date of this report,  Inamco International Corp.
carried out an evaluation,  under the supervision and with the  participation of
the Company's management,  including the Company's Chief Executive and Principal
Accounting  Officer,  of the  effectiveness  of the design and  operation of the
Company's  disclosure  controls  and  procedures  pursuant to Exchange  Act Rule
13a-14. Based upon that evaluation, the Chief Executive and Principal Accounting
Officer  concluded  that the Company's  disclosure  controls and  procedures are
effective in timely alerting him to material information required to be included
in the Company's periodic SEC filings relating to the Company.

(b)      Changes in Internal Controls.

There were no significant changes in the Company's internal controls or in other
factors that could  significantly  affect these internal controls  subsequent to
the date of my most recent evaluation.

PART II. OTHER INFORMATION

ITEM 4. EXHIBITS AND REPORTS ON FORM 8-K

  (a) Exhibits

None.

  (b) Reports on Form 8-K None.




                                       11

<PAGE>



                                   SIGNATURES

    Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.
                                         INAMCO INTERNATIONAL, CORP.

Dated:  August 20, 2003                  By:   /s/ VARGES GEORGE
                                            ----------------------------------
                                               Name: Varges George
                                            Title: President and Chief
                                               Executive Officer




                                       12

<PAGE>

      CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL ACCOUNTING
               OFFICER PURSUANT TO 18 U.S.C 1350, AS ADOPTED, AND
        THE REQUIREMENTS OF SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

         I, Varges  George,  Chief  Executive  Officer and Principal  Accounting
Officer of Inamco International, Corp. (the "Company") do hereby certify that:

         1. I have reviewed this quarterly report on Form 10-QSB of the Company;

         2. Based on my knowledge,  this  quarterly  report does not contain any
untrue  statement of a material fact or omit to state a material fact  necessary
to make the  statements  made,  in light of the  circumstances  under which such
statements  were made, not misleading with respect to the period covered by this
quarterly report; and

         3. Based on my knowledge, the financial statements, and other financial
information  included in this quarterly  report,  fairly present in all material
respects the financial  condition,  results of operations  and cash flows of the
Company as of, and for, the period presented in this quarterly report.

         4.  I  am  responsible  for  establishing  and  maintaining  disclosure
controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for
the Company and have:

             (a) designed such disclosure controls and procedures to ensure that
      material  information  relating  to the  Company,  is made  known to me by
      others  within the Company,  particularly  during the period in which this
      quarterly report is being prepared;

             (b)  evaluated  the  effectiveness  of  the  Company's   disclosure
      controls  and  procedures  as of a date within 90 days prior to the filing
      date of this quarterly report (the "Evaluation Date"); and

             (c) presented in this  quarterly  report my  conclusions  about the
      effectiveness  of the  disclosure  controls  and  procedures  based  on my
      evaluation as of the Evaluation Date;

         5. I  have  disclosed,  based  on my  most  recent  evaluation,  to the
Company's  auditors and the audit  committee of the Company's board of directors
(or persons performing the equivalent functions):

             (a) all  significant  deficiencies  in the design or  operation  of
      internal  controls which could adversely  affect the Company's  ability to
      record,  process,  summarize and report financial data and have identified
      for  the  registrant's   auditors  any  material  weaknesses  in  internal
      controls; and

             (b) any fraud, whether or not material, that involves management or
      other  employees  who have a significant  role in the  Company's  internal
      controls; and

         6. I have indicated in this quarterly  report whether or not there were
significant  changes  in  internal  controls  or in  other  factors  that  could
significantly  affect internal controls subsequent to the date of my most recent
evaluation,   including  any  corrective  actions  with  regard  to  significant
deficiencies and material weaknesses.

                                           /s/  Varges George
                                           ------------------------------
                                           Chief Executive Officer and
                                           Principal Accounting Officer

August 20, 2003





                                       13


<PAGE>